These findings imply that IL-6 levels within the tumor microenvironment (TME) may be increased upon treatment with the TGFβ vaccine, potentially due to the polarization of CAFs by TGFβ-specific T cells toward an increased IL-6-secreting phenotype. The gene discussed is TGFB1; the disease is neoplasm.